Global Biosimilars Market to 2019: Regulatory Frameworks and Product Pipelines Report Available at ReportsnReports.com

ReportsnReports.com adds “PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market” to its store. Lucrative Biosimilars Space to Erode Biologics Market from 2019.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
ReportsnReports.com

ReportsnReports.com

Dallas, Texas (PRWEB) July 08, 2014

The increasing prevalence of biosimilars will have a noticeably negative impact on the biologics market beyond 2019, despite an initial projected Compound Annual Growth Rate (CAGR) of 8.3%, taking the overall biologics market value from $162 billion in 2013 to more than $262 billion by 2019.

The company’s latest report “PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market” states that patent expiration of branded biologics and the introduction of clearer regulatory frameworks for biosimilars after 2019 will see the latter capturing the market share from biologics.

There are a number of factors driving the initiative towards the global adoption of biosimilars, from austerity measures and slow economic growth in the US, to an aging population and increasing demand for healthcare in countries such as Japan. The savings made from choosing biosimilars over biologics are not as substantial as first anticipated, and the cost of biosimilars is expected to be around 20-30% lower than that of branded biologic therapies. This remains a significant reduction nonetheless, since many biologics command hundreds of thousands of dollars for one year’s treatment.

Complete Report Available @ http://www.reportsnreports.com/reports/291514-pharmasphere-regulatory-frameworks-and-product-pipelines-in-the-global-biosimilars-market.html.

While many biologic manufacturers are seeking to slow the entry of biosimilars into the market, GlobalData’s report states that the biosimilars arena is attracting attention from contract manufacturing organizations, such as Lonza and Celltrion, along with contract research organizations, including Quintiles and Paraxel, and multi-industry conglomerates, such as Samsung and LG.

The biosimilars industry is already highly lucrative. More than 100 deals involving companies focused on the development of biosimilars have been completed over the past seven years, with a total value in excess of $10.7 billion. In addition to private ventures, some national governments are targeting the biosimilars market to sustain their domestic pharmaceutical industries. Most significantly, South Korea announced in 2011 that it aims to create approximately 120,000 new jobs in the sector, in a bid to capture 22% of the global biosimilars market by 2020.

Key Questions Answered
What are the drivers of the global biosimilars industry?

  •     Who are the top players involved in the development of biosimilars in the developed markets of Europe and the US, as well as in emerging markets, including India and China?
  •     What are the major barriers to entry into the biosimilars industry?
  •     What specific strategies are companies utilizing to combat some of the challenges currently facing the development of the global biosimilars industry?
  •     What is the current state of biosimilars regulation in the EU, US, Japan, India, China, and South Korea?

Order a purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=291514.

Scope

  •     The report provides analysis of the key drivers and trends shaping the global biosimilars industry.
  •     The report discusses the biosimilar regulatory landscape of various markets including developed markets of the US and EU, as well as emerging markets such as China and India. Furthermore, it identifies key domestic players in the various markets discussed and provides analysis of their strategy, manufacturing capacity, and clinical pipeline.
  •     The report contains expert insights on the corporate strategies of current and prospective players in the global biosimilars industry.
  •     The report contains a special case study on Teva Pharmaceutical Industries' biosimilars business, including an in-depth SWOT analysis of the company.

Reasons to buy

  •     Understand the frameworks under which biosimilars are currently being reviewed and regulated across various developed and emerging markets
  •     Identify the key domestic players in various biosimilar markets, including South Korea, Japan and emerging markets such as India and China
  •     Understand the key drivers and trends in the global biosimilars industry
  •     Analyze and track the strategies that companies are using to enter and/or strengthen their position in the rapidly evolving biosimilars industry, as well as efforts being made by innovator companies like Amgen to protect their market position
  •     Use this information as an independent source for your due diligence and transaction strategy

Inquire before buying @ http://www.reportsnreports.com/contacts/InquiryBeforeBuy.aspx?name=291514.

Table of Contents
1 Table of Contents
2 Introductions
3 Market Overview
4 Biosimilar Deals Trends
5 Biosimilars Regulation
6 Biosimilars in the US
7 Biosimilars in Europe
8 Biosimilars in Japan
9 Biosimilars in India
10 Biosimilars in South Korea
11 Biosimilars in China
12 Case Study: Teva Pharmaceutical Industries
13 Strategic Outlook
14 Appendix

Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/.

About Us:
ReportsnReports.com is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. We provide 24/7 online and offline support service to our customers.


Contact

Follow us on: Contact's Google Plus